pS2 and response to adjuvant hormone therapy in primary breast cancer.

Por Spyratos, F., Andrieu, C., Hacène, K., Chambon, P., Rio, M. C.
Publicado em 1994

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Por Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A., Oglobine, J.
Publicado em 1994

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

Por Rouleau, E, Spyratos, F, Dieumegard, B, Guinebretière, J M, Lidereau, R, Bièche, I
Publicado em 2008

Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Por Escot, C, Theillet, C, Lidereau, R, Spyratos, F, Champeme, M H, Gest, J, Callahan, R
Publicado em 1986

Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.

Por Perrot-Applanat, M., Groyer-Picard, M. T., Vu Hai, M. T., Pallud, C., Spyratos, F., Milgrom, E.
Publicado em 1989

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Por Bouchet, C., Spyratos, F., Hacène, K., Durcos, L., Bécette, V., Oglobine, J.
Publicado em 1998

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study

Por Broët, P, Spyratos, F, Romain, S, Quillien, V, Daver, A, Ricolleau, G, Rallet, A, Toulas, C, Asselain, B
Publicado em 1999

Comparison of a new microplate oestrogen receptor (ER) enzyme immunoassay with other ER detection methods.

Por Delage, V., Deytieux, S., Le Doussal, V., Degorce, F., Bellanger, L., Hacene, K., Seguin, P., Descotes, F., Saez, S., Spyratos, F.
Publicado em 1997

Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.

Por Pichon, M. F., Broet, P., Magdelenat, H., Delarue, J. C., Spyratos, F., Basuyau, J. P., Saez, S., Rallet, A., Courriere, P., Millon, R., Asselain, B.
Publicado em 1996

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

Por Cizkova, M, Dujaric, M-E, Lehmann-Che, J, Scott, V, Tembo, O, Asselain, B, Pierga, J-Y, Marty, M, de Cremoux, P, Spyratos, F, Bieche, I
Publicado em 2013

Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas

Por Fina, F, Romain, S, Ouafik, L'H, Palmari, J, Ayed, F Ben, Benharkat, S, Bonnier, P, Spyratos, F, Foekens, J A, Rose, C, Buisson, M, Gérard, H, Reymond, M O, Seigneurin, J M, Martin, P M
Publicado em 2001

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

Por Mauriac, L, Luporsi, E, Cutuli, B, Fourquet, A, Garbay, J R, Giard, S, Spyratos, F, Sigal-Zafrani, B, Dilhuydy, J M, Acharian, V, Balu-Maestro, C, Blanc-Vincent, M P, Cohen-Solal, C, De Lafontan, B, Dilhuydy, M H, Duquesne, B, Gilles, R, Lesur, A, Shen, N, Cany, L, Dagousset, I, Gaspard, M H, Hoarau, H, Hubert, A, Monira, M H, Perrié, N, Romieu, G
Publicado em 2003